- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.09. | Bluejay Diagnostics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Bluejay Diagnostics, Inc.: Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets | 2 | GlobeNewswire (USA) | ||
| 13.08. | Bluejay Diagnostics reports Q2 results | 1 | Seeking Alpha | ||
| 13.08. | Bluejay Diagnostics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.08. | Bluejay Diagnostics completes enrollment in sepsis test study | 1 | Investing.com | ||
| BLUEJAY DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony IL-6 Toward Regulatory Submission and Commercialization | 450 | GlobeNewswire (Europe) | SYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate... ► Artikel lesen | |
| 12.08. | Bluejay Diagnostics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.07. | Bluejay Diagnostics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study | 283 | GlobeNewswire (Europe) | ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today... ► Artikel lesen | |
| 09.06. | Bluejay Diagnostics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.06. | Bluejay Diagnostics closes $8.5 million private placement | 1 | Investing.com | ||
| 06.06. | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 03.06. | What's Going On With Bluejay Diagnostics Shares On Wednesday? | 3 | Benzinga.com | ||
| 02.06. | Bluejay Diagnostics raises $8.5M in private placement | 2 | Investing.com | ||
| 02.06. | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 4 | GlobeNewswire (USA) | ||
| 02.06. | Why Is Bluejay Diagnostics Stock Soaring Tuesday? | 7 | Benzinga.com | ||
| 02.06. | Morning Market Movers: Bluejay Diagnostics, Decent Holding, Abits Group, Sunshine Biopharma See Big Swings | 780 | AFX News | WASHINGTON (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 02.06. | Bluejay Diagnostics partners with Argonaut for US manufacturing | 4 | Investing.com | ||
| 02.06. | Bluejay Diagnostics, Inc.: Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership | 260 | GlobeNewswire (Europe) | ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company") (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing... ► Artikel lesen | |
| 02.06. | Bluejay Diagnostics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARL ZEISS MEDITEC | 31,100 | +1,37 % | Aktien KW 38 Warsh konnte nicht bremsen. Iran verhindert mehr. TACO gefragt! News. Rheinmetall. Mutares. Verbio. Lufthansa. Hapag Lloyd. Carl Zeiss MediTec. Verbio. BASF. DEFAMA. Vonovia. Aroundtown. SFC Energy. Dürr. Evonik. Continental. Elmos Semiconduc | Aktien - es gab eine Leitzinserhöhung in den USA. Da von allen erwartet konnten die Aktienmärkte damit relativ gut umgehen. Selbst Gold und Silber atmeten einmal kurz ein udn setzten danach zum neuen... ► Artikel lesen | |
| TELADOC HEALTH | 5,364 | -0,30 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| HIMS & HERS HEALTH | 24,880 | -0,24 % | Hims and Hers Is Scaling Rapidly, But Management Needs To Address The Difficult Questions | ||
| SERNOVA BIOTHERAPEUTICS | 0,060 | -6,52 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| CERENOME | 1,616 | -3,46 % | CNSide Diagnostics signs agreement with Blue Cross Michigan | ||
| ATOSSA THERAPEUTICS | 1,890 | -2,58 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| GE HEALTHCARE TECHNOLOGIES | 57,85 | -0,36 % | GE HealthCare (GEHC) is Down 28% and Wall Street is Starting to Buy. Is the Selloff Finally Over? | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,400 | 0,00 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,090 | -0,91 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| QUIDELORTHO | 9,482 | +4,34 % | QuidelOrtho Corp - 8-K, Current Report | ||
| VERU | 2,450 | -0,41 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,000 | 0,00 % | Lifeward Ltd.: Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer | HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 3,940 | -1,75 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 8,700 | -1,14 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen |
BLUEJAY DIAGNOSTICS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,963 Euro und damit -0,63 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BLUEJAY DIAGNOSTICS INC finden Sie auf Wallstreet Online.